iNKT cells

BIOLOGICAL3 trials

Sponsors

Beijing YouAn Hospital

Conditions

Hepatocellular Carcinoma

Phase 1

Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC

CompletedNCT03175679

Beijing YouAn HospitalHepatocellular Carcinoma

Start: 2017-04-01End: 2019-03-30Updated: 2024-09-19

Phase 2

Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC

CompletedNCT04011033

Beijing YouAn HospitalHepatocellular Carcinoma

Start: 2018-03-01End: 2023-10-01Updated: 2024-10-08

Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy

RecruitingNCT05962450

Beijing YouAn HospitalHepatocellular Carcinoma

Start: 2023-10-26End: 2025-08-01Target: 84Updated: 2024-01-16

Related Papers

593 Efficacy of invariant natural killer T cell infusion plus transarterial embolization vs transarterial embolization alone for hepatocellular carcinoma patients: a phase 2 randomized clinical trial

Regular and Young Investigator Award Abstracts2023-10-311 citations

Efficacy of Invariant Natural Killer T Cell Infusion Plus Transarterial Embolization vs Transarterial Embolization Alone for Hepatocellular Carcinoma Patients: A Phase 2 Randomized Clinical Trial

Journal of Hepatocellular Carcinoma2023-08-0120 citations

Adoptive Transfer of Autologous Invariant Natural Killer T Cells as Immunotherapy for Advanced Hepatocellular Carcinoma: A Phase I Clinical Trial

The Oncologist2021-07-1337 citations